Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report

Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of...

Full description

Bibliographic Details
Main Authors: Cirino Botta, Rita Maria Agostino, Vincenzo Dattola, Vittoria Cianci, Natale Daniele Calandruccio, Giovanna Bianco, Antonino Mafodda, Roberto Maisano, Eleonora Iuliano, Giovanna Orizzonte, Domenico Mazzacuva, Antonia Consuelo Falzea, Rita Emilena Saladino, Rocco Giannicola, Giorgio Restifo, Umberto Aguglia, Michele Caraglia, Pierpaolo Correale
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
urothelial cancer
PD1-checkpoint inhibitors
class-I/II HLA
myasthenia
Online Access:https://www.mdpi.com/1422-0067/22/12/6246

Internet

https://www.mdpi.com/1422-0067/22/12/6246

Similar Items